Evidence map›Paper›PMID 19176740›Full record

ReviewThe American journal of clinical nutrition2009

Leptin in humans: lessons from translational research.

Susann Blüher, Christos S Mantzoros

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in The American journal of clinical nutrition, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02320110 (Correlation of Circulating Irisin and Adipokine Levels Across a Broad Spectrum of Body Mass Index Ranging From Undernourished to Obese and With Insulin Resistance and Risk Factors for the Metabolic Syndrome in Hispanic Children), which is not on this map. Cited by 72 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 2 pooled it
8.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02320110 completednot on this mapstarted 2014, after this paper: background citation

Correlation of Circulating Irisin and Adipokine Levels Across a Broad Spectrum of Body Mass Index Ranging From Undernourished to Obese and With Insulin Resistance and Risk Factors for the Metabolic Syndrome in Hispanic Children

TypeobservationalSponsorInstituto Tecnologico y de Estudios Superiores de MontereyRan2014 to 2014Enrolled40ConditionsOverweight, Obesity, Thinness
3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 2 syntheses or guidelines pooled it, 199 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Review
  9. Review
  10. Neuroendocrinological and Clinical Aspects of Leptin.Mini reviews in medicinal chemistry · 2024
    Review
  11. Review
  12. Does eating less or exercising more to reduce energy availability produce distinct metabolic responses?Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2023
    Review
  13. Article
  14. Review
  15. Article
  16. Observational
  17. Review
  18. Treatment Options for Lipodystrophy in Children.Frontiers in endocrinology · 2022
    Review
  19. Impaired Leptin Signalling in Obesity: Is Leptin a New Thermolipokine?International journal of molecular sciences · 2021
    Review
  20. Article

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Susann BlüherHospital for Children and Adolescents, University of Leipzig, Germany
Christos S Mantzoros
Beth Israel Deaconess Medical Center · US

Funding

Role of Leptin in the Neuroendocrine Response to FastingR01DK058785 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI MANTZOROS, CHRISTOS S · 2001 to 2011
$4.0M
The Role of Leptin in the Maintenance of a Reduced Body WeightR01DK079929 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI MANTZOROS, CHRISTOS S · 2008 to 2012
$1.8M
Role of Leptin in the Neuroendocrine Response to FastingR56DK058785 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI MANTZOROS, CHRISTOS S · 2005 to 2005
$85k
NIDDK NIH HHS DK 58785NIDDK NIH HHS DK 79929
6 · The paper itself

Abstract

Leptin has emerged over the past decade as a key hormone in not only the regulation of food intake and energy expenditure but also in the regulation of neuroendocrine and immune function as well as the modulation of glucose and fat metabolism as shown by numerous observational and interventional studies in humans with (complete) congenital or relative leptin deficiency. These results have led to proof-of-concept studies that have investigated the effect of leptin administration in subjects with complete (congenital) leptin deficiency caused by mutations in the leptin gene as well as in humans with relative leptin deficiency, including states of lipoatrophy or negative energy balance and neuroendocrine dysfunction, as for instance seen with hypothalamic amenorrhea in states of exercise-induced weight loss. In those conditions, most neuroendocrine, metabolic, or immune disturbances can be restored by leptin administration. Leptin replacement therapy is thus a promising approach in several disease states, including congenital complete leptin deficiency, states of energy deprivation, including anorexia nervosa or milder forms of hypothalamic amenorrhea, as well as syndromes of insulin resistance seen in conditions such as congenital or acquired lipodystrophy. In contrast, states of energy excess such as garden-variety obesity are associated with hyperleptinemia that reflects either leptin tolerance or leptin resistance. For those conditions, development of leptin sensitizers is currently a focus of pharmaceutical research. This article summarizes our current understanding of leptin's role in human physiology and its potential role as a novel therapeutic option in human disease states associated with a new hormone deficiency, ie, leptin deficiency.

Indexed as

AnimalsHumansLeptinNeurosecretory SystemsLeptin

Identifiers

PMID19176740
PMCPMC2667664
OpenAlexW2085745363

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.